Global Bacterial Vaginosis Scope 2025, Forecast To 2034
26 Mar, 2025
How Has the Bacterial Vaginosis Market Size Evolved in Recent Years?
The bacterial vaginosis market has seen considerable growth due to a variety of factors.
• In the past few years, the bacterial vaginosis market has experienced significant expansion. The projection shows an increase from $3.03 billion in 2024 to $3.32 billion in 2025, with a compound annual growth rate (CAGR) of 9.7%.
Factors contributing to this anticipated growth during the historical period include more widespread use of point-of-care diagnostics, the expansion of e-commerce, an increase in unsafe sexual practices, a boost in STI vaccination rates, and improved healthcare accessibility.
What Is The Forecast For The Bacterial Vaginosis Market?
The bacterial vaginosis market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, a robust expansion is anticipated in the bacterial vaginosis market, predicting it to reach a value of $4.75 billion in 2029, with a CAGR of 9.4%.
The proposed growth in the forecasted years can be linked to factors such as a surge in bacterial vaginosis cases, an elevated demand for functional foods, a rise in STI cases, an increase in women’s health issues, and a heightened awareness on menopause. Significant trends for the forecast period entail the utilization of artificial intelligence in diagnostic processes, the use of probiotics, improvements in home-based STI testing, and the uptake of environmentally-friendly materials in women's health devices.
Gain Insights Into The Bacterial Vaginosis Global Market Report 2025 With A Free Sample Report Here:
What Factors Are Driving Growth In The Bacterial Vaginosis Market?
The rise in sexually transmitted infections (STIs) is projected to contribute significantly to the expansion of the bacterial vaginosis market. STIs involve infections majorly transmitted through sexual activities, and they can be triggered by bacteria, parasites, or viruses. The escalating occurrence of STIs can be attributed to factors including unprotected intercourse, a multitude of partners, ignorance, and antibiotic resistance. An increase in bacterial vaginosis boosts the risk of STIs by shifting the vaginal bacterial equilibrium, thereby providing a conducive environment for infections like HIV and chlamydia to manifest. For instance, in March 2024, reported cases surged notably compared to the prior year, as per the European Centre for Disease Prevention and Control (ECDC), a Swedish governmental agency. Specifically, gonorrhea increased by 48%, syphilis by 34%, and chlamydia by 16%. As such, the upsurge in sexually transmitted infections (STIs) is spurring the development of the bacterial vaginosis market.
How Is The Global Bacterial Vaginosis Market Divided Into Key Segments?
The bacterial vaginosis market covered in this report is segmented –
1) By Type: Point-Of-Care Testing, Laboratory Testing, Other Types
2) By Product: Below 15 Years, Between 15-45, Other Products
3) By Application: Antibiotics, Other Applications
4) By End-User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Point-Of-Care Testing: Rapid Diagnostic Tests, Microscopy-based Tests, Immunoassays
2) By Laboratory Testing: Gram Staining, Polymerase Chain Reaction (PCR), DNA Probe Tests, Culture-based Testing
3) By Other Types: Home Testing Kits, Enzyme-linked Immunosorbent Assay (ELISA)
What Trends Are Reshaping The Future Of The Bacterial Vaginosis Market?
To augment the diagnosis and treatment process, many leading firms in the bacterial vaginosis market are working on groundbreaking solutions like multiplexed polymerase chain reaction (PCR) tests. These are PCR tests that permit the dual enhancement and identification of several target DNA or RNA sequences in a single PCR trial. For instance, Cepheid, a biotech research company based in the US, launched the Xpert Xpress Multiplex Vaginal Panel (MVP) in November 2022. Capable of giving quick results in less than an hour, this panel recognizes three vaginal infections: bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), and trichomoniasis (TV) from one specimen. It accommodates both clinician-collected and self-collected swabs by utilizing automated real-time PCR technology, thus enhancing diagnostic precision and bettering treatment results for women. The broad application of this technology across different clinical settings ensures efficient and accurate detection of vaginal infections.
Who Are the Key Players In The Bacterial Vaginosis Market?
Major companies operating in the bacterial vaginosis market are:
• Pfizer Inc.
• Merck & Co. Inc.
• Merck KGaA
• Bayer AG
• Sanofi SA
• Thermo Fisher Scientific
• Becton Dickinson
• Viatris Inc.
• Otsuka Pharmaceutical
• LabCorp
• Quest Diagnostics
• Organon & Co.
• UT Southwestern Medical Center
• Hologic Inc.
• bioMérieux SA
• Shionogi & Company Limited
• Melinta Therapeutics Inc.
• Evofem Biosciences
• Gedea Biotech
• Fleurstat
• Medical Diagnostic Laboratories
What Are The Regional Insights Into The Bacterial Vaginosis Market?
North America was the largest region in the bacterial vaginosis market in 2024. The regions covered in the bacterial vaginosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.